KRAS mutational status in japanese patients with colorectal cancer: Results from a nationwide, multicenter, cross-sectional study

Japanese Journal of Clinical Oncology

Volumn 43, Issue 7, 2013, Pages 706-712

  Watanabe, Toshiaki ^a   Yoshino, Takayuki ^b   Uetake, Hiroyuki ^c   Yamazaki, Kentaro ^d   Ishiguro, Megumi ^c   Kurokawa, Tatsuo ^e   Saijo, Nagahiro ^f   Ohashi, Yasuo ^g   Sugihara, Kenichi ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d SHIZUOKA CANCER CENTER   (Japan)

^e KEIO UNIVERSITY   (Japan)

^f Japanese Society of Medical Oncology   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

Author keywords

Age; Gender; KRAS; Risk factor; Site

Indexed keywords

FORMALDEHYDE; GENOMIC DNA; K RAS PROTEIN; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CODON; COLORECTAL CANCER; CROSS-SECTIONAL STUDY; DNA EXTRACTION; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUTATION RATE; OBSERVATIONAL STUDY; ONCOGENE K RAS; WILD TYPE;

AGE; GENDER; KRAS; RISK FACTOR; SITE;

ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL NEOPLASMS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RISK FACTORS; SEX FACTORS;

EID: 84880174405     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt062     Document Type: Article

References (33)

1. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007;7:295-308.
2. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
3. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
4. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
5. NCCN (National Comprehensive Cancer Networkw). Clinical Practice Guidelines in OncologyTM Colon Cancer V.3 2011.
6. NICE (National Institute for Health and Clinical Excellence). Technology Appraisal Guidance 176. Cetuximab for the First-line Treatment of Metastatic Colorectal Cancer 2010.
7. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J Natl Cancer Inst 1998;90:675-84.
8. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466-74.
9. Sobin LH, Gaspodarowicz M, Wittekind Ch. TNM classfication of Malignant Tumors. 7th edn. New York:Wiley-Blackwell 2009.
10. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on National Survival Outcomes Data. J Clin Oncol 2010;28:264-71.
11. van Krieken JH, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008;453:417-31.
12. Shinozaki E, Mizunuma N, Yoshino T, et al.. Luminexw Assay-A Novel, Simple and Cost-effective Detection Method for KRAS Mutation: Results from a Multi-center, Subjective Clinical Trial [abstract]. Presented at the 35th European Society for Medical Oncology Congress, Milan, Italy 2010;182.
13. Zlobec I, Molinari F, Kovac M, et al. Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients. Br J Cancer 2010;102:151-61.
14. Abubaker J, Bavi P, Al-Haqawi W, et al. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol 2009;219:435-45.
15. Barault L, Veyrie N, Jooste V, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008;122:2255-9.
16. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000;9:1193-7.
17. Ferreira CG, Zalcberg-Renault I, Vieira FM, et al. Analysis of KRAS mutations in colorectal cancer (CRC) patients by gender in a Brazilian cohort of 3,346 patients [abstract]. J Clin Oncol 2010;28(15, Suppl.): 3614.
18. Horii J, Hiraoka S, Kato J, et al. Methylation of estrogen receptor 1 in colorectal adenomas is not age-dependent, but is correlated with K-ras mutation. Cancer Sci 2009;100:1005-11.
19. Kawakami K, Ruszkiewicz A, Bennett G, et al. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer 2006;27:593-8.
20. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
21. Konishi M, Kikuchi-Yanoshita R, Tanaka K, et al. Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. Gastroenterology 1996;111:307-17.
22. Fujiwara T, Stolker JM, Watanabe T, et al. Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. Am J Pathol 1998;153:1063-78.
23. Yamagata S, Muto T, Uchida Y, et al. Polypoid growth and K-ras codon 12 mutation in colorectal cancer. Cancer 1995;75:953-7.
24. Umetani N, Sasaki S, Masaki T, Watanabe T, Matsuda K, Muto T. Involvement of APC and K-ras mutation in non-polypoid colorectal tumorigenesis. Br J Cancer 2000;82:9-15.
25. Hiraoka S, Kato J, Tatsukawa M, et al. Laterally spreading type of colorectal adenoma exhibits a unique methylation phenotype and K-ras mutations. Gastroenterology 2006;131:379-89.
26. Mukawa K, Fujii S, Takeda J, et al. Analysis of K-ras mutations and expression of cyclooxygenase-2 and gastrin protein in laterally spreading tumors. J Gastroenterol Hepatol 2005;20:1584-90.
27. Kaku E, Oda Y, Murakami Y, et al. Proportion of flat- and depressed-type and laterally spreading tumor among advanced colorectal neoplasia. Clin Gastroenterol Hepatol 2011;9:503-8.
28. Goto K, Ishii G, Todo T, et al.. Validation Study of EGFR Mutation Tests using DNA from Control Admixture Samples and Formalin-fixed Paraffin-embedded (FFPE) Samples from Non-small-cell lung Cancer (NSCLC) Patients in the Diagnostic Setting [abstract]. Presented at the 35th European Society for Medical Oncology Congress, Milan, Italy 2010;382.
29. Bando H, Tsuchihara K, Yoshino T, et al. Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing. Jpn J Clin Oncol 2011;41:239-44.
30. Watanabe T, Kobunai T, Yamamoto Y, et al. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum 2011;54:1170-8.
31. Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009;27:2622-9.
32. Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 2008;13:1270-5.
33. Suchy B, Zietz C, Rabes HM. K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis. Int J Cancer 1992;52:30-3